Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1899

Aortic Stenosis Is Increased in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Compared to Other Forms of Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1898

Are There Risk Factors for Calcinosis in Scleroderma?

9:00AM-11:00AM: Abstract Number: 1903

Assessment of Subclinical Atherosclerosis in Patients with Systemic Sclerosis: Results from a Multicentric Cohort

9:00AM-11:00AM: Abstract Number: 1883

Association of Myocardial Abnormalities with Disease Characteristic and Brain Natriuretic Peptide (BNP) in Systemic Sclerosis without Cardiac Symptoms As Assessed Using Cardiac Magnetic Resonance Imaging; A Prospective Multi Center Study

9:00AM-11:00AM: Abstract Number: 1901

Association of Serum Adipokines Adipsin, Adiponectin, and Leptin/Adiponectin Ratio with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1894

Calcium Channel Blockers Are More Effective in the Treatment of Primary Raynaud’s Phenomenon Compared to Secondary: A Meta-Analyis

9:00AM-11:00AM: Abstract Number: 1876

Caveolin 1 Gene Variants May Effect Disease Progression in Systemic Sclerosis Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1880

Circulating Microparticle Populations May Differentiate Between Connective Tissue Diseases.

9:00AM-11:00AM: Abstract Number: 1895

Correlation of Scleroderma Interstitial Lung Disease with Gastroesophageal Reflux

9:00AM-11:00AM: Abstract Number: 1875

Deep Vein Thrombosis and Pulmonary Embolism in Systemic Sclerois

9:00AM-11:00AM: Abstract Number: 1887

Deficiency in Micronutrients Is a Frequent Burden in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1904

Development of the Mawdsley Calcinosis Questionnaire (MCQ) Version 1 – a Patient-Reported Outcome Measure (PROM) for Systemic Sclerosis Related Calcinosis (SSc-Ca)

9:00AM-11:00AM: Abstract Number: 1878

Diagnostic Performance of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis: Results from a Brazilian Validation Cohort

9:00AM-11:00AM: Abstract Number: 1896

Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation

9:00AM-11:00AM: Abstract Number: 1889

Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease

9:00AM-11:00AM: Abstract Number: 1897

Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1885

Identification and Clinical Correlations of Rare Autoantibodies in Systemic Sclerosis and Poly/Dermatomyositis Patients

9:00AM-11:00AM: Abstract Number: 1879

Immunosuppressive “Routine”� Treatment of SSc Patients with Limited Cutaneous Involvement and Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1892

Impact of Cardiac Magnetic Resonance Imaging with T1 Mapping and Multi-b Value Diffusion-Weighted Sequences in Systemic Sclerosis for the Assessment of Myocardial Microscopic Fibrosis and Perfusion

9:00AM-11:00AM: Abstract Number: 1874

Impact of Socioeconomic Status on Survival in Connective Tissue Disease Associated and Idiopathic Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1873

Inter and Intrarater Reliability of the Modified Rodnan Skin Score in Early Diffuse Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1881

Is the Presence of Esophageal Dilation a Poor Prognostic Factor in Dilated Interstitial Lung Disease Associated with Systemic Sclerosis?

9:00AM-11:00AM: Abstract Number: 1886

Myocardial Fibrosis Detected By Magnetic Resonance Imaging Is a Predictor of Heart Failure in Systemic Sclerosis (SSc) Patients

9:00AM-11:00AM: Abstract Number: 1891

Parameters That Predict Worsening of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1900

Performance of the Detect Protocol for Pulmonary Arterial Detection in Systemic Sclerosis Patients in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1877

Prevalence and Risk Factors for Left Ventricular Diastolic Dysfunction in Scleroderma

9:00AM-11:00AM: Abstract Number: 1893

Relationship Between Vitamin D Levels and Disease Activity in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1884

Sensitivity to Change of Nailfold Videocapillaroscopy and Relationship with Disease Progression

9:00AM-11:00AM: Abstract Number: 1890

Subclinical Biventricular Systolic Function Is Impaired in Patients with Systemic Sclerosis with Real Time 3-D Echpcardiography: 1 Year Follow-up Study

9:00AM-11:00AM: Abstract Number: 1872

Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma

9:00AM-11:00AM: Abstract Number: 1902

Systemic Sclerosis and Lung Cancer Risk: Data from the Canadian Scleroderma Research Group

9:00AM-11:00AM: Abstract Number: 1882

The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1888

There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].